Current status of immune checkpoint inhibitor therapy for advanced esophageal squamous cell carcinoma.

Enomoto, Naoki; Yamada, Kazuhiko; Terayama, Masayoshi; Kato, Daiki; Yagi, Shusuke; Wake, Hitomi; Takemura, Nobuyuki; Kiyomatsu, Tomomichi; Kokudo, Norihiro

Enomoto, Naoki; Yamada, Kazuhiko; Terayama, Masayoshi; Kato, Daiki; Yagi, Shusuke; Wake, Hitomi; Takemura, Nobuyuki; Kiyomatsu, Tomomichi; Kokudo, Norihiro.

Afiliación

Enomoto N; Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan.
Yamada K; Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan.
Terayama M; Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan.
Kato D; Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan.
Yagi S; Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan.
Wake H; Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan.
Takemura N; Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan.
Kiyomatsu T; Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan.
Kokudo N; Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan.

Glob Health Med ; 3(6): 378-385, 2021 Dec 31.

Article en En | MEDLINE | ID: mdl-35036619

Palabras clave

esophageal squamous cell carcinoma; immune checkpoint inhibitor; nivolumab; pembrolizumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Glob Health Med Año: 2021 Tipo del documento: Article País de afiliación: Japón

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google